Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT

Maiwand Ahmadsei; Kai Thaler; Elena Gasser; Bertrand Pouymayou; Riccardo Dal Bello; Sebastian M Christ; Jonas Willmann; Boldizsar Kovacs; Panagiotis Balermpas; Stephanie Tanadini-Lang; Ardan M Saguner; Michael Mayinger; Nicolaus Andratschke; Matthias Guckenberger

doi:10.1016/j.ctro.2023.100675

Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT

Clin Transl Radiat Oncol. 2023 Sep 13:43:100675. doi: 10.1016/j.ctro.2023.100675. eCollection 2023 Nov.

Authors

Affiliations

¹ Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
² Department of Cardiology, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
³ Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, Zurich University Hospital, University of Zurich, 8952 Schlieren, Switzerland.

Abstract

•Data on cardiac toxicity after SBRT for ultra-central lung tumors remains limited.•We analyzed the dose to 18 cardiac sub-structures and cardiovascular toxicity.•A SBRT regimen of 45 Gy in 8-10 fractions yields good local control and low toxicity.•The highest cardiac doses were observed in the pulmonary artery and left atrium.•Higher doses to the base of the heart seem to be associated with non-cancer deaths.

Keywords: Cardiac sub-structures; Cardiac toxicity; SBRT; Stereotactic body radiotherapy; Ultra-central lung tumors.